Business UpdateMay 28, 2026, 04:31 PM
Tonix Presents Fibromyalgia Opioid Data, Supports TONMYA Launch
AI Summary
Tonix Pharmaceuticals presented real-world claims analysis data on opioid use in U.S. adults with fibromyalgia at the 2026 ASCP Annual Meeting. The analysis of over 261,000 patients in 2023-2024 demonstrated a substantial and persistent health burden associated with prescribed opioid use. This data supports the urgent need for non-opioid, FDA-approved treatments like Tonix's TONMYA, which was commercially launched in November 2025 as the first new fibromyalgia drug in over 15 years. The study highlighted high rates of opioid prescription across various insurance types and age groups, along with significant concomitant opioid and benzodiazepine use.
Key Highlights
- Tonix presented real-world claims data on opioid use in fibromyalgia at ASCP 2026.
- Analysis covered over 261,000 U.S. adults with fibromyalgia in 2023-2024.
- 40.2% of commercially/Medicare Advantage insured patients were prescribed at least one opioid.
- 38.8% of Medicaid patients were prescribed at least one opioid.
- Opioid use was highest in the 61-65 age group (43.1%).
- 19.1% of commercially/Medicare Advantage patients had concomitant opioid and benzodiazepine use.
- TONMYA was commercially launched in November 2025, approved by FDA in August 2025.
- TONMYA is the first new FDA-approved fibromyalgia drug in over 15 years.
Price Impact
More from TNXP